Sandoz Abandons US Development of Rixathon
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the implications of Sandoz’s abandoned attempt to...
Read More...
Focus:
-
![]()
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...
Read More...
-
![]()
Industry Viewpoints: Choosing the Right CRO
In this Industry Viewpoint, CTA’s Elizabeth Williams speaks with Philip Arlen to discuss key considerations...
Read More...
-
![]()
The United Kingdom of Green Britain
As medicinal cannabis hits the U.K., CTA’s Harry Parsons takes a look at the ground-breaking...
Read More...
-
![]()
Expert Insights: EMA Reinforces Stance on Biosimilar Use for Sustainable Health Care in New Educational Video
Chloé Thépaut, MRes, Oncology Senior Analyst, GlobalData, examines the importance of the EMA’s efforts to...
Read More...
-
![]()
The Top 5: September 2018
CTA highlights the best articles from the month of September 2018
Read More...
-
![]()
A Question to Sponsors – Have We Gone Too Far?
Jennifer Brandl, Clinical Trial Manager, Kezar Life Sciences, addresses a key hurdle to overcome to...
Read More...
-
![]()
Patient-Centric Clinical Trials │ How to Navigate the Clinical Trials Highway
Robert Greene, Founder and President, HungerNdThirst Foundation and Professional Patient, explains why patients should have...
Read More...
-
![]()
Industry Viewpoints: Investigator-Initiated Studies – A Challenge for Supply with IMPs?
Peter Orosz, Head of Clinical Supply Chain Management & Oncology, Boehringer Ingelheim, addresses the challenges...
Read More...
-
![]()
Expert Insights: What Does the Future Hold for US Biosimilars?
Fern Barkalow, PhD, Oncology and Hematology Director, GlobalData, explores the future of biosimilars in light...
Read More...
